US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021

URL

https://jamanetwork.com/journals/jama/fullarticle/2779731

Authors

Isaac See, John R. Su, Allison Lale, Emily Jane Woo, Alice Y. Guh, Tom T. Shimabukuro, Michael B. Streiff, Agam K. Rao, Allison P. Wheeler, Suzanne F. Beavers, Anna P. Durbin, Kathryn Edwards, Elaine Miller, Theresa A. Harrington, Adamma Mba-Jonas, Narayan Nair, Duong T. Nguyen, Kawsar R. Talaat, Victor C. Urrutia, Shannon C. Walker, C. Buddy Creech, Thomas A. Clark, Frank DeStefano, and Karen R. Broder

Published Date

April 30, 2021

Publication

JAMA (Journal of the American Medical Association)

Organization

CDC (Centers for Disease Control & Prevention) COVID-19 Response Team

Key Excerpts

“Question: What were the clinical characteristics of the first US patients reported to have cerebral venous sinus thrombosis (CVST) with thrombocytopenia following receipt of the Ad26.COV2.S (Janssen/Johnson & Johnson) COVID-19 vaccine?

Findings: In this case series of 12 patients, all were women, younger than 60 years, and had symptom onset ranging from 6 to 15 days after vaccination requiring hospitalization. Of 11 patients with heparin-platelet factor 4 enzyme-linked immunosorbent assay (ELISA) heparin-induced thrombocytopenia (HIT) antibody test results, all were positive. At last follow-up, outcomes were death (n = 3), intensive care unit (ICU) care (n = 3), non-ICU hospitalization (n = 2), and discharge to home (n = 4).”

Medium

document

Topics

adverse events,COVID-19,vaccines,vascular system issues